Mallikarjuna Rao Gedda

Mallikarjuna Rao Gedda

Auto-generated profile, based on publicly available information

Mallikarjuna Rao Gedda

Population Sciences Branch, National Heart

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MGMallikarjuna Rao Gedda
Mallikarjuna Rao Gedda
BSBhawana Singh
Bhawana Singh
DKDhiraj Kumar
Dhiraj Kumar
ASAbhishek Kumar Singh
Abhishek Kumar Singh
PMPrasoon Madhukar
Prasoon Madhukar
SSShyam Sundar
Shyam Sundar
Leishmaniasis remains a public health concern around the world that primarily affects poor folks of the developing world spanning across 98 countries with mortality of 0.2 million to 0.4 million annually. Post kala-azar dermal leishmaniasis (PKDL) is the late skin manifestation of visceral leishmaniasis (VL). It has been reported that about 2.5% to 20% of patients recovered from VL develop PKDL having stilted macular or nodular lesions with parasites. In the Indian subcontinent (ISC), it manifests a few months after recovery from VL, though in Africa it can occur simultaneously with VL or a little later. New cases of PKDL are also observed without prior VL in the ISC. These individuals with PKDL represent an important but largely neglected reservoir of infection that perpetuates anthroponotic Leishmania donovani transmission in the ISC and can jeopardize the VL elimination program as these cases can infect the sand flies and spread the endemic. Therefore, it becomes imperative to eradicate PKDL as a part of the VL elimination program. With the limited treatment options besides little knowledge on PKDL, this review stands out in focusing on different aspects that should be dealt for sustained VL elimination.

3 November 2020 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
MGMallikarjuna Rao Gedda
Mallikarjuna Rao Gedda
PMPrasoon Madhukar
Prasoon Madhukar
ASAshish Shukla
Ashish Shukla
SMShyam Lal Mudavath
Shyam Lal Mudavath
OSOnkar Nath Srivastava
Onkar Nath Srivastava
SSShyam Sundar
Shyam Sundar

17 June 2025 in ACS Omega
Verified
Journal Article
Open access
PMPrasoon Madhukar
Prasoon Madhukar
RKRashmi Kesarwani
Rashmi Kesarwani
SPSundaram Pandey
Sundaram Pandey
VSVishal Kumar Singh
Vishal Kumar Singh
MGMallikarjuna Rao Gedda
Mallikarjuna Rao Gedda
SSShyam Sundar
Shyam Sundar
Visceral Leishmaniasis (VL) is a life-threatening parasitic disease primarily affecting populations in resource-limited, endemic regions. Existing treatments for VL face limitations such as toxicity, high costs, and suboptimal efficacy in specific patient groups. Given the lack of a vaccine, chemotherapy remains the only option, emphasizing the urgent need for safer and more effective treatments. Nanotechnology offers promising avenues to overcome these challenges. This study introduces a novel approach involving amine-functionalized graphene quantum dots (fGQDs) conjugated with Amphotericin B (fGQDAmB) to enhance targeted drug delivery to Leishmania-infected macrophages. This novel approach, which could lead to a safer and more effective treatment for VL, is a significant contribution to the field. Structural characterization by XRD and FTIR confirmed successful GQD synthesis and functionalization, while cellular assays demonstrated significantly higher macrophage uptake and enhanced antileishmanial efficacy. fGQDAmB demonstrated approximately 4.2-fold greater potency against intracellular amastigotes and 2-fold higher efficacy against promastigotes, while also exhibiting reduced cytotoxicity compared to conventional AmB. The safety and effectiveness of fGQDAmB were further validated through hemolysis assay, providing reassurance and confidence about its potential use and instilling confidence in the potential of Quantum Dot-based Nanomedicine formulations.